Full Text View
Tabular View
Study Results
Related Studies
An Open-label Study of NRP104 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
This study has been completed.
Study NCT00337285   Information provided by New River Pharmaceuticals
First Received: June 9, 2006   Last Updated: August 19, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Attention Deficit Disorder with Hyperactivity
Disease
Hyperkinesis
More general conditions related to this trial
Attention Deficit and Disruptive Behavior Disorders
Dyskinesias
Mental Disorders
Mental Disorders Diagnosed in Childhood
Nervous System Diseases
Neurologic Manifestations
Pathologic Processes
Signs and Symptoms
Additional drug interventions recognized in this trial
Dextroamphetamine
More general drug interventions related to this trial
Central Nervous System Agents
Central Nervous System Stimulants
Dopamine Agents
Dopamine Uptake Inhibitors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
New River Pharmaceuticals
Shire Pharmaceutical Development


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services